Skip to content

Exercise Activity-Based Bolus Decisions in Type 1 Diabetes

A Pilot Study of Activity-Based Bolus Decisions in Type 1 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03394352
Enrollment
15
Registered
2018-01-09
Start date
2018-01-17
Completion date
2018-05-11
Last updated
2018-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

Type 1 Diabetes Mellitus, Insulin pump, Continuous Glucose Monitor (CGM), Exercise, Activity on Board, Decision Support System

Brief summary

The purpose of the study is to demonstrate safety and feasibility of a decision support system aimed at improving activity-related insulin boluses in Type 1 Diabetes.

Detailed description

Subjects with Type 1 diabetes often need to adjust insulin boluses for activity since activity may increase the chance of hypoglycemia. The aims of this study is to make better bolus decisions by integrating knowledge about daily physical activity (PA) into bolus decisions. It is expected to decrease risk of hypoglycemia related to previous PA and provide better glucose control. The idea is to first obtain a carbohydrate ratio that is optimized around the everyday activity level of the patient and then adjust boluses when the activity for the day is different (above or below) than their regular activity level.

Interventions

OTHERActivity on Board

During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.

Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.

Sponsors

DexCom, Inc.
CollaboratorINDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Type 1 Diabetes for at least one year 2. Using an insulin pump for at least 6 months 3. Age 18-65 4. Uses insulin parameters such as carbohydrate ratio and correction factors consistently on the insulin pump in order to dose insulin for meals or corrections 5. Access to internet and willing to upload data during the study 6. Willingness to maintain consistent activity regimen for 28 day collection period 7. Females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while participating in the study. A negative urine/blood pregnancy test will be required for all women of child bearing potential. Subjects who become pregnant will be discontinued from the study. 8. Demonstration of proper mental status and cognition for the study. 9. An understanding of and willingness to follow the protocol and sign the informed consent.

Exclusion criteria

1. Diabetic ketoacidosis (DKA) in the 6 months prior to enrollment. 2. Severe hypoglycemia resulting in seizure or loss of consciousness in the 6 months prior to enrollment. 3. Pregnancy and intent to become pregnant during trial. 4. Use of acetaminophen is not allowed when CGM is in use 5. Use of non-insulin medications intended to lower glucose (e.g. glucagon-like peptide \[GLP\]-1 agonists, metformin) 6. Currently uses a clearly defined method for insulin bolusing to compensate for significant activity (e.g. marathon runner who uses temporary basal rates routinely and has separate basal profiles to account for exercise) 7. Inability to be physically active for more than 30 minutes per day. 8. Current enrollment in another intervention clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Continuous Glucose Monitor metricsabout 9-12 hoursRecord CGM metrics with the primary outcome analysis of percentage time \<70 mg/dL by CGM following exercise comparing the experimental to control admission

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026